Latest Yield News

Marmota Limited’s maiden drilling program at the Greenewood gold discovery in South Australia reveals spectacular bonanza-grade gold assays over nearly 1km strike length, positioning the project as a standout in the Gawler Craton.

Auravelle Metals’ maiden aircore drilling at the Crown Gold Project near Kalgoorlie confirms widespread supergene gold anomalism over 2km, identifying multiple promising targets for follow-up drilling.

Dreadnought Resources has reported impressive high-grade results from recent drilling at its Stinger target, part of the Mangaroon Project in Western Australia, highlighting significant rare earths, niobium, titanium, scandium, and phosphate mineralisation.

Fisher & Paykel Healthcare has updated its dividend announcement to include the Australian Dollar equivalent, providing clearer insight for investors ahead of the mid-December payment.

Rand Mining has released a replacement exploration report for the East Kundana Joint Venture, highlighting new JORC disclosures and promising high-grade gold assay results from the Ambition prospect.

Tribune Resources has replaced its initial FY2026 Q1 EKJV exploration report with a more detailed version, revealing promising high-grade gold assay results and enhanced compliance disclosures.

St Barbara Limited has completed a compelling restart study for its Touquoy gold project in Nova Scotia, outlining a low-capital, near-term operation with robust economics and a positive permitting outlook.

CVC Limited has issued $75 million in redeemable, unsecured notes set to trade on the ASX from December 11, offering investors an attractive 8.2% interest rate starting March 2026.

Bayan Mining has locked in an exclusive worldwide licence for advanced rare earth processing technologies developed at Colorado School of Mines, promising higher recovery rates and lower costs for its Desert Star Project near Mountain Pass.

Star Minerals has received mining approval for its Tumblegum South Gold Project, setting the stage for mining to commence in early 2026. With robust production targets and a key partnership in place, the project is poised to advance swiftly.

Mayne Pharma has rejected Cosette Pharmaceuticals’ notice to terminate their merger agreement, citing Cosette’s failure to meet obligations that led to regulatory approval issues. The dispute raises fresh uncertainty over the proposed acquisition’s future.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.